1. Home
  2. APPN vs XERS Comparison

APPN vs XERS Comparison

Compare APPN & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Appian Corporation

APPN

Appian Corporation

HOLD

Current Price

$25.33

Market Cap

1.8B

Sector

Technology

ML Signal

HOLD

XERS

Xeris Biopharma Holdings Inc.

HOLD

Current Price

$8.78

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
APPN
XERS
Founded
1999
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.5B
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
APPN
XERS
Price
$25.33
$8.78
Analyst Decision
Hold
Buy
Analyst Count
5
6
Target Price
$29.80
$10.83
AVG Volume (30 Days)
754.3K
2.3M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
101.59
100.00
EPS
N/A
0.01
Revenue
$226,743,000.00
$49,590,000.00
Revenue This Year
$13.79
$34.37
Revenue Next Year
$10.56
$22.86
P/E Ratio
N/A
$860.00
Revenue Growth
28.29
142.67
52 Week Low
$18.63
$4.87
52 Week High
$46.06
$10.08

Technical Indicators

Market Signals
Indicator
APPN
XERS
Relative Strength Index (RSI) 60.55 68.64
Support Level $19.45 $7.89
Resistance Level $27.25 $9.02
Average True Range (ATR) 1.15 0.37
MACD 0.16 -0.01
Stochastic Oscillator 69.86 76.93

Price Performance

Historical Comparison
APPN
XERS

About APPN Appian Corporation

Appian Corp is a low-code enterprise platform-as-a-service company focusing on business process management. The company's Appian platform is an integrated automation platform providing tools for organizations to design, automate, and optimize end-to-end processes and complex business operations. The company also provides maintenance and support as well as consulting services and training related to its platform. The majority of its revenue is subscription-based with the remainder from services, with much of its subscription revenue being derived from its cloud-based platform. Geographically, the company derives maximum revenue from its Domestic operations, and also has its presence Internationally.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

Share on Social Networks: